Published in Medical Letter on the CDC and FDA, February 27th, 2005
According to scientists in the United States, "Nitric oxide (NO)-derived products may modify tissue constituents, forming S- and N-nitroso adducts and metal nitrosyls implicated in NO signaling. Nitrovasoclilator drugs have been in widespread use for more than a century, yet their biotransformation pathways to NO and their effects as NO donors across tissues remain ill defined."
D.R. Janero and colleagues of Boston University reported, "By using a metabonomics approach (termed 'NObonomics') for detailing the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA